In this episode, FDA grants fast track designation to REM-001; practice-changing treatment advances continue; proton partial breast radiotherapy appears effective and more. Read the full coverage here: FDA grants fast track designation to REM-001 for cutaneous metastatic breast cancer Practice-changing treatment advances continue in early-stage triple-negative breast cancer Proton partial breast radiotherapy appears effective, safe for early breast cancer New endocrine therapy options for patients with breast cancer on the horizon, expert says Use of contraception decreases after breast cancer diagnosis References: Choi JI, et al. Clin Transl Radiat Oncol. 2022;doi:10.1016/j.ctro.2022.08.013 Healio Interviews Lambertini M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetowrkopen.2022.33137. Press Release Traina TA, et al. Early-stage triple-negative breast cancer. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.

Ver todos los episodios